• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.

    5/15/25 4:15:29 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYCN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Cyclerion Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, no par value

    (Title of Class of Securities)


    23255M204

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23255M204


    1Names of Reporting Persons

    Tyndall Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    164,777.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    164,777.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    164,777.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 2 for additional information.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cyclerion Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    245 First Street, 18th Floor, Cambridge, Massachusetts
    Item 2. 
    (a)Name of person filing:

    The reporting person is Tyndall Capital Partners, L.P. ("Reporting Person"). As of March 31, 2025, 164,777 shares are owned by Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"). Reporting Person is the general partner of Tyndall, and possesses the sole power to vote and the sole power to direct the disposition of all shares held by Tyndall.
    (b)Address or principal business office or, if none, residence:

    150 East 58th Street, 14th Floor, New York, New York 10155
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock, no par value
    (e)CUSIP No.:

    23255M204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    164,777
    (b)Percent of class:

    5.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    164,777

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    164,777

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Tyndall Capital Partners, L.P.
     
    Signature:/s/ Jeffrey S. Halis
    Name/Title:Jeffrey S. Halis, Manager of Jeffrey Management LLC, its general partner
    Date:05/15/2025
    Get the next $CYCN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYCN

    DatePrice TargetRatingAnalyst
    10/20/2021$14.00Buy
    Truist Securities
    9/24/2021$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

    CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced an update on its progress in catalyzing the Company's next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution. "These agreements demonstrate Cyclerion's progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets," said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. "These newly finalized agreements, combined with our significant redu

    12/17/24 8:08:11 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regina Graul, Ph.D., Promoted to Chief Executive Officer

    CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion's operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited. "From the day Regina arrived at Cyclerio

    8/7/24 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close

    12/4/23 8:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Chicko Rhonda M.

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    8/11/25 4:05:06 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hecht Peter M was granted 181,818 shares, increasing direct ownership by 48% to 559,203 units (SEC Form 4)

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    3/27/25 8:38:03 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Higgins Michael J was granted 9,090 shares, increasing direct ownership by 42% to 30,740 units (SEC Form 4)

    4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)

    3/27/25 4:20:44 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cyclerion Therapeutics Inc.

    SCHEDULE 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    8/14/25 4:05:22 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cyclerion Therapeutics Inc.

    10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)

    8/5/25 4:30:55 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Cyclerion Therapeutics Inc.

    8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)

    6/18/25 4:41:21 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist Securities initiated coverage on Cyclerion Therapeutics with a new price target

    Truist Securities initiated coverage of Cyclerion Therapeutics with a rating of Buy and set a new price target of $14.00

    10/20/21 7:03:08 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Cyclerion Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Cyclerion Therapeutics with a rating of Overweight and set a new price target of $7.00

    9/24/21 7:19:43 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Appoints Regina Graul, Ph.D., as President

    – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close

    12/4/23 8:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

    Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer's Disease with vascular pathology (ADv) enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update. "The data generated from our recent

    8/9/22 4:00:00 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

    CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. "We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research program

    7/26/22 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc.

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    7/12/24 6:17:25 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    2/14/24 4:05:40 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclerion Therapeutics Inc. (Amendment)

    SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)

    2/9/24 5:06:49 PM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care